A Randomized Phase III Study Exploring the Efficacy of Capecitabine Given Concomitantly or in Sequence to EC-Doc [epirubicin + cyclophosphamide + docetaxel] With or Without Trastuzumab as Neoadjuvant Treatment of Primary Breast Cancer.

Trial Profile

A Randomized Phase III Study Exploring the Efficacy of Capecitabine Given Concomitantly or in Sequence to EC-Doc [epirubicin + cyclophosphamide + docetaxel] With or Without Trastuzumab as Neoadjuvant Treatment of Primary Breast Cancer.

Completed
Phase of Trial: Phase III

Latest Information Update: 05 Jul 2017

At a glance

  • Drugs Capecitabine (Primary) ; Cyclophosphamide; Docetaxel; Epirubicin; Trastuzumab
  • Indications Early breast cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms GeparQuattro
  • Most Recent Events

    • 05 Jul 2017 Results assessing prognostic value of circulating tumor cells detected before and after neoadjuvant therapy, published in the Clinical cancer research: an official journal of the American Association for Cancer Research
    • 13 May 2016 Results of pooled sub-group analysis assessing PIK3CA mutations from GeparQuattro, GeparQuinto, GeparSixto, NeoALTTO and CHERLOB trials (n=967) published in the Annals of Oncology
    • 14 Dec 2013 Predictive biomarker analysis presented at the 36th Annual San Antonio Breast Cancer Symposium.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top